Pliant Therapeutics
PLRX
97 hedge funds and large institutions have $57.6M invested in Pliant Therapeutics in 2025 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 30 increasing their positions, 33 reducing their positions, and 14 closing their positions.
7% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 14
6% less call options, than puts
Call options by funds: $231K | Put options by funds: $247K
9% less repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 33
2% less funds holding
Funds holding: 99 → 97 (-2)
6.05% less ownership
Funds ownership: 82.11% → 76.06% (-6.1%)
23% less capital invested
Capital invested by funds: $74.7M → $57.6M (-$17.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
BML Capital Management
Zionsville,
Indiana
|
+$2.32M |
| 2 |
PM
Prosight Management
Dallas,
Texas
|
+$2.31M |
| 3 |
MAM
Monaco Asset Management
Monaco
|
+$1.68M |
| 4 |
CC
Centiva Capital
New York
|
+$1.5M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$1.17M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$6.45M |
| 2 |
Morgan Stanley
New York
|
-$4.44M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$3.72M |
| 4 |
JP Morgan Chase
New York
|
-$1.38M |
| 5 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$1.26M |
PLRX Hedge Fund Activity: Q4 2025 in Review
97 of the 8,267 institutional investors tracked by Wall St. Rank reported a position in Pliant Therapeutics (PLRX) for Q4 2025, worth a combined $57.6M — down 23% from $74.7M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new PLRX positions and 14 closed out — a net gain of 1 holder — while 30 added to existing stakes and 33 trimmed.
The largest buyer was BML Capital Management, opening a new position worth an estimated $2.32M. The largest seller was Point72 Asset Management, cutting an estimated $6.45M.
- 97 institutional investors held Pliant Therapeutics (PLRX) as of Q4 2025, down from 99 in Q3 2025.
- Funds reported $57.6M of Pliant Therapeutics stock for Q4 2025, down 23% quarter-over-quarter.
- 15 funds opened new Pliant Therapeutics positions in Q4 2025 and 14 closed out, a net change of +1 holder.
- The largest Pliant Therapeutics buyer in Q4 2025 was BML Capital Management, an estimated $2.32M added.
- The largest Pliant Therapeutics seller in Q4 2025 was Point72 Asset Management, an estimated $6.45M sold.
Based on aggregated 13F filings for Q4 2025.